Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (9603)	6/15/1998 9:08:00 PM
From: Edderd	Read Replies (2) \| Respond to of 23519

VLAD IMO you are grasping at straws when you expect Pfizer to add all hypertensive meds to the precaution listing. There is no science to support this action. There will have to be definitive (or at least strong statistical) evidence to even consider it. I agree that the largest part of the V market is related to a weak weenie not a dead weapon and so there is room for many other players. I still believe the oriental market is ripe for the urethral system and am looking forward to seeing the demand and sales from that area; If I can wait that long. Ed